Artificial intelligence is moving from pilot projects to practical tools across the NHS. The policy direction is clear, with a shift to community-based care and a focus on prevention, personalisation and operational efficiency. Public confidence is not keeping pace. Surveys conducted in 2025 reveal low baseline trust in AI advice and persistent concerns about data privacy, algorithmic bias, and the loss of human contact in consultations. Pharmacists sit at the centre of this tension. They combine daily access to patients, deep medical expertise and a consistently high trust rating among health professionals. This positions them to act as the human interface that translates complex models into safe, equitable, and person-centred practice. This feature evaluates the evidence and policy architecture behind that role, describes current operational and clinical use cases, and outlines safeguards that enable the model to function at scale.
The policy context shaping AI adoption across the NHS
The government strategy outlines a long-term transition to a digitally enabled health service, with more care delivered close to home. The 10-year plan highlights a stronger role for community services and a mandate to modernise pharmacy. A linked national programme prioritises AI for decision support, operational productivity, and non-clinical workflows. The structure is phased. Governance and controlled pilots come first, followed by scaling through diagnostics and workflow tools, and then deeper precision use cases after 2028. The centrepiece is a Single Patient Record that unifies data across settings and will surface to citizens through the NHS App. The record underpins interoperability, auditability and fair access to information. Without it, predictive and preventive use cases lack the necessary breadth of data for safety and validity.
Public trust and professional attitudes in 2025
Polling in 2025 records a gap between policy ambition and public sentiment. A majority of UK adults report reluctance to use AI for medical consultations, and an even larger share do not trust standalone AI to provide safe advice. Younger adults show similar caution. Professional views are mixed but pragmatic. Many GPs expect AI to reduce administrative burden and to improve information capture. Most people do not believe that AI improves empathetic communication. They fear substitution risks if patients lean on chat tools rather than booking care. The shared pattern is the acceptance of AI in back-office functions, accompanied by caution at the clinical frontline. Trust is higher when a clinician remains in control and the tool is framed as clinical decision support rather than an autonomous decision maker.
A real fact: is that across trusted roles in 2025, general practitioners retain the highest public confidence, while pharmacists also score strongly, and AI systems sit near the bottom of the trust league. Human oversight is therefore a non-negotiable expectation for clinical use.
Why pharmacists are positioned to mediate AI
The pharmacist’s scope now spans medicines optimisation, minor ailment management, vaccination, public health support and chronic disease monitoring. Community locations make access simple, and repeat contacts build continuity. The same counter that dispenses medicines also fields questions about side effects, interactions and adherence. These working patterns align with the strengths of AI as a pattern finder and a prompt engine. They also align with the limits. A model can flag a potential problem, but a pharmacist must validate the signal, review context, and communicate risk in plain language. The pharmacist closes the loop by translating an output into an action that reflects the patient’s preference, comorbidities, and practical constraints.
Building blocks for a single patient record and data standards
The Single Patient Record serves as the reference layer, making community-based decision support credible. It collates medication histories, allergies, diagnostic data and recent clinical notes. For the pharmacist, this reduces blind spots, supports reconciliations and speeds safety checks. For AI, it provides representative inputs and a lawful route to access them. Two roles follow. Pharmacists use data to inform care decisions and contribute clean, structured data to the patient’s record. Recording vaccinations, blood pressure checks, adherence conversations and side effect reports expands the dataset that future models learn from. Data standards and access controls are essential. They define provenance, limit secondary use and enable audit trails that attribute changes to specific users or systems.
Operational automation freeing clinical time in pharmacy
AI first proves value behind the counter. Automated storage and retrieval systems, linked to machine learning vision modules, now handle stock put-away and picking with high speed and reliability. Labelling units that detect pack orientation and font layout reduce errors and accelerate throughput, freeing time equivalent to a full-time role in some sites. Forecasting models utilise sales patterns and local epidemiology to predict demand and prevent stockouts. Generative AI assists with routine communications, meeting summaries and report drafting. These tools do not directly add clinical value. They remove low-value tasks so pharmacists can redirect time to consultations, medicine reviews and public health interventions.
Clinical decision support in medicines optimisation
Decision support is adequate when it aligns with the pharmacist’s workflow and respects accountability. The most immediate applications are safety checks and structured reviews.
Interaction and contraindication checking. Real-time analysis of prescriptions can flag interactions, duplicate therapies and dose anomalies. Alerts linked to patient-specific factors such as renal function or pregnancy improve precision. The pharmacist evaluates the alert, checks the context and intervenes with the prescriber when necessary.
Therapeutic monitoring prompts. Rules-based and learning systems can prompt follow-up tests, such as thyroid function tests for long-term amiodarone use or potassium levels for ACE inhibitor titration. Prompts reduce missed monitoring and support guideline concordance.
Deprescribing support. Pattern recognition across age, multimorbidity and anticholinergic burden can surface candidates for review. The pharmacist applies judgment, weighs the benefit against the risk and builds a plan that the patient can follow.
Adherence insights. Data from refill patterns, messaging and self-reports can suggest non-adherence. The pharmacist explores causes, simplifies regimens where possible and aligns solutions with patient priorities.
Across each case, the model proposes and the professional disposes. Documentation records the decision and the rationale in the Single Patient Record for continuity.
Risk stratification and proactive public health
Predictive tools can identify people at higher risk of adverse drug events, deterioration or readmission. In a neighbourhood model, the pharmacist uses these lists to target reviews and education. The same approach supports antimicrobial stewardship by highlighting patterns in local consumption and resistance. The pharmacist can then adjust advice, reinforce delayed prescriptions where appropriate, or escalate suspected sepsis promptly. For long-term conditions such as diabetes or COPD, dashboards that integrate prescribing, monitoring, and symptom data can guide stepped care and support self-management
Communication duties that sustain patient trust
Human communication is the difference between a warning and a workable plan. Pharmacists should describe AI support in clear terms, specifying what the tool can and cannot do. They should explain data uses, retention and rights of objection. They should invite questions and record preferences. When an AI output informs a recommendation, that fact should be included in the note, along with a brief justification that ties to accepted standards. These habits preserve transparency and make later audits more straightforward. They also align with the public’s expectation that a qualified professional remains responsible for the outcome.
Ethical and regulatory guardrails for safe deployment
Regulation in 2025 relies on evolving guidance and regulatory sandboxes. Principles are stable even as rules mature. Data used for training and validation must be relevant, representative and lawfully processed. Systems should be monitored after deployment to detect drift and bias. Risk assessments must include the potential equality impacts, with mitigations for groups that are most likely to be harmed by error. Tools should clearly expose their performance characteristics and known limitations. User interfaces should support safe defaults, and override functions must be easily accessible and well-documented. Most importantly, workflows must preserve human-in-the-loop control at points where safety depends on value judgements.
Digital literacy and workforce transformation
Standards for initial education now require capability in data and technology. The practising workforce needs the same uplift. Short courses in data governance, prompt design, model limitations and error handling build confidence. Simulation and case-based learning sharpen practical skills. Local digital champions within pharmacy teams help colleagues integrate tools without compromising professional standards. Upskilling counter staff and technicians is also relevant. As automation handles more dispensing, teams can support history-taking, device teaching, and signposting under the supervision of a pharmacist.
Implementation roadmap for community pharmacy
A structured plan enhances the likelihood of safe and effective deployment.
1. Map tasks and choose targets. Identify processes that consume time but do not require clinical judgement. Pick one operational tool and one clinical tool with clear success metrics.
2. Prepare data and governance. Confirm lawful bases for data access. Map data flows to the Single Patient Record: Configure access controls and audit logging. Define escalation routes.
3. Design workflows with users. Build steps that place the pharmacist at validation points. Keep interfaces simple. Avoid alert overload by focusing on high-risk rules first.
4. Train and rehearse. Run tabletop scenarios for common edge cases to identify and address potential issues. Teach teams how to document AI-assisted decisions.
5. Start small and measure. Pilot at one site. Track accuracy, time saved, intervention rates and patient feedback. Review equality impacts.
6. Iterate and scale. Address pain points, update guidance, and expand to additional use cases once results are stable.
Measuring impact with meaningful metrics
Evidence should capture safety, efficiency and equity.
Safety. Rate of prevented dispensing errors, reduction in high-risk interactions, adherence to monitoring prompts, and documented overrides with justification.
Efficiency. Time saved per task, consultations delivered per full-time equivalent, turnaround time for prescription queries and stockout rates.
Equity. Performance by age group, deprivation quintile and ethnicity where data are available. False positive and false negative rates across subgroups.
Experience. Patient reported clarity and trust, staff confidence in using tools, and prescriber feedback on the relevance of pharmacist queries.
Limitations, uncertainties and research needs
Several constraints remain. Many reported gains come from single-site examples and early deployments. Generalisability is uncertain. Data quality varies across different settings, which in turn affects the performance of models. Drift over time requires maintenance resources that organisations may not have budgeted. There is a risk that enthusiasm for automation could deskill teams if supervision is weak. Digital exclusion is a live concern in communities with low access or confidence. Rigorous studies that compare AI-supported models with standard care on hard outcomes are still limited. Future work should prioritise multicentre trials, robust post-market surveillance, and open reporting of both failures and successes.
Practical guidance for day one safe use
Keep three rules at the counter. First, always verify identity and context before acting on an alert. Second, document the involvement of AI when it shapes a decision, including the clinical reasoning that led to acceptance or rejection. Third, disclose data uses in simple language and record consent or objections. If a tool’s output conflicts with clinical sense, stop and escalate. Use double checks for high-risk medicines and vulnerable patients. Develop a concise library of standard explanations for common concerns about AI in healthcare, and then tailor them to meet the individual’s specific needs.
Conclusion: moving from pilots to trusted practice
UK health policy is aligning capacity, data, and community access to support AI-enabled care. Public confidence will follow only when people see competent professionals using tools to make their care safer and more personal. Pharmacists are well placed to make that case every day. They convert predictions into actions, catch edge cases that models miss, and explain choices in language patients understand. Think of AI as a microscope. It sharpens detail, but it still needs a trained eye to interpret the view and act on it. When that trained eye belongs to a pharmacist at the heart of a neighbourhood team, AI shifts from scepticism to alliance and from promise to practice.
